Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Cariprazine For Acute And Maintenance Treatment Of Adults With Schizophrenia: An Evidence-Based Review And Place In Therapy, Leslie L. Citrome
Cariprazine For Acute And Maintenance Treatment Of Adults With Schizophrenia: An Evidence-Based Review And Place In Therapy, Leslie L. Citrome
NYMC Faculty Publications
Cariprazine is an oral antipsychotic approved in the US and EU for the treatment of schizophrenia. Cariprazine differs from other antipsychotics in that it is a dopamine D3- and D2-receptor partial agonist, with tenfold higher affinity for D3 receptors than for D2 receptors. Cariprazine is metabolized in two steps by CYP3A4 to didesmethyl-cariprazine (DDCAR). DDCAR has a long half-life of 1-3 weeks and is the predominant circulating active moiety. Efficacy and safety in persons with acute schizophrenia were assessed in four similarly designed, short-term, randomized, placebo-controlled clinical trials in nonelderly adults, with three studies considered positive and yielding a number …
Relapse Prevention: A Cost-Effectiveness Analysis Of Brexpiprazole Treatment In Adult Patients With Schizophrenia In The Usa, Myrlene Aigbogun, Sizhu Liu, Siddesh Kamat, Christophe Sapin, Amy Duhig, Leslie L. Citrome
Relapse Prevention: A Cost-Effectiveness Analysis Of Brexpiprazole Treatment In Adult Patients With Schizophrenia In The Usa, Myrlene Aigbogun, Sizhu Liu, Siddesh Kamat, Christophe Sapin, Amy Duhig, Leslie L. Citrome
NYMC Faculty Publications
Objective: This study used a decision-analytic framework to assess the cost-effectiveness of brexpiprazole vs comparator branded therapies for reducing relapses and hospitalizations among adults with schizophrenia from a US payer perspective. Methods: An economic model was developed to assess patients with stable schizophrenia initiating treatment with brexpiprazole (1-4 mg), cariprazine (1-6 mg), or lurasidone (40-80 mg) over a 1-year period. After 6 months, patients remained on treatment or discontinued due to relapse, adverse events, or other reasons. Patients who discontinued due to relapse or adverse events were assumed to have switched to other therapy, and those who discontinued due to …
Psychodynamic Psychiatrists' Experiences Of Being Stalked, Douglas Ingram
Psychodynamic Psychiatrists' Experiences Of Being Stalked, Douglas Ingram
NYMC Faculty Publications
Despite the estimated 15% likelihood that a psychiatrist will become the victim of stalking, there is little formal recognition of its prevalence or its impact on well-being. Through narrative accounts, ten psychiatrists with psychodynamic orientations speak of their experiences including how each managed the anxieties consequent to stalking. These include a variety of adaptive psychic operations as well as concrete actions to curtail stalking.